Introduction {#Sec1}
============

Obesity is an increasing epidemic worldwide \[[@CR1], [@CR2]\] that is associated with significant morbidity. Metabolic and bariatric surgery (MBS) has been proven as a safe and effective treatment option for severe obesity that is associated with durable weight loss, improvement and resolution of comorbid conditions \[[@CR3]--[@CR6]\], reduced cancer risk, increased longevity \[[@CR7], [@CR8]\], and improved quality of life \[[@CR9], [@CR10]\].

Given the increasing safety profile of MBS, there is an increasing interest in its role in higher-risk patient cohorts, including transplant candidates and patients. This increasing practice trend is driven by data showing that 2--12% of patients awaiting solid organ transplantation meet the criteria for severe obesity (body mass index (BMI) \> 35 kg/m^2^) \[[@CR11]\] and weight loss prior to organ transplantation results in better perioperative outcomes and improved graft survival \[[@CR12], [@CR13]\]. While limited to small case series and single-institution experience, there is growing evidence suggesting that MBS can be a safe and effective weight loss treatment option in patients with previous solid organ transplant (PSOT) \[[@CR11]--[@CR16]\].

While obesity has increased among all demographics in the USA, the prevalence and health impact disproportionately impact racial and ethnic minority patients \[[@CR1]--[@CR3], [@CR17]--[@CR20]\] who continue to be an underrepresented cohort of MBS patients. Even though MBS is overall safe and effective \[[@CR3]--[@CR10]\], there remains a controversy regarding the safety profile and effectiveness of MBS surgery in racial and ethnic cohorts, with some studies reporting no outcome differences \[[@CR21]--[@CR23]\] while others report higher rates of adverse outcomes in racial and ethnic minority patients \[[@CR24], [@CR25]\].

No published data exists on outcomes in racial and ethnic MBS patient cohorts with PSOT. Therefore, the goal of this study goal was to compare outcomes between black and white MBS patients with a history of PSOT to determine if race was an independent predictor of perioperative outcomes.

Material and Methods {#Sec2}
====================

Data Source {#Sec3}
-----------

A retrospective analysis of the 2017 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Participant Use Files (PUF) database was performed, and outcomes between racial cohorts of MBS patients with PSOT were compared. The MBSAQIP is responsible for the accreditation of bariatric surgical facilities. Requirements for certification includes reporting bariatric surgical outcomes to the MBSAQIP Participant Use Data File (PUF), a Health Insurance Portability and Accountability Act (HIPAA)-compliant data file registry containing prospectively entered, risk-adjusted, clinically rich data using standardized definitions for preoperative, intraoperative, and postoperative variables that are specific to metabolic and bariatric surgical care. Data points are abstracted at participating institutions by certified reviewers who are audited for accuracy of performance. The 2017 file included data on a composite variable of previous solid organ transplantation (PSOT), including a history of heart, lung, liver, renal, pancreas, and bowel transplantation. This is a de-identified, nationally available, clinical database; therefore, neither institutional review board (IRB) approval nor patient consent was required for our study.

Case Selection and Inclusion Criteria {#Sec4}
-------------------------------------

Our inclusion and exclusion criteria are detailed in Fig. [1](#Fig1){ref-type="fig"}. Patients with PSOT undergoing primary gastric bypass (RYGB) or sleeve gastrectomy (SG) cases were identified through Current Procedural Terminology (CPT) codes 43644, 43645, and 43775. Exclusions included bariatric procedure other than a RYGB or SG, bariatric procedures designated as emergency, open cases, surgical approach other than robotic-assisted or conventional laparoscopy, and other races including American Indian or Alaska Native, Asian, Native Hawaiian, or Other Pacific Islands and Unknown. Selected cases were further stratified by race (non-Hispanic black vs. non-Hispanic white).Fig. 1Inclusion and exclusion flow diagram. MBSAQIP = Metabolic and Bariatric Surgery Accreditation and Quality Improvement Project, BMI = body mass index, TXP = transplantation

Data Collection, Matching, and Statistical Analysis {#Sec5}
---------------------------------------------------

Descriptive statistics were collected and compared between groups, including demographics, health summary status, preoperative comorbidities, and operative characteristics. Primary outcome measures included 30-day mortality and morbidity. Secondary outcome measures included other 30-day adverse outcomes (reoperation, readmission, and reintervention), postoperative complication, aggregate complications (Appendix Table [7](#Tab7){ref-type="table"}), and hospital outcomes (operative duration, conversion, and hospital length of stay). Propensity score--matched analyses were performed to adjust for intergroup biases. The matching ratio was one-to-one. A logistic regression model was generated on patient demographics and variables with a *p* \< 0.1 on univariate analysis between racial cohorts with prior solid organ transplantation. Variables included in our regression model were Hispanic ethnicity, hypertension (HTN), chronic steroid use, obstructive sleep apnea (OSA), dialysis-dependent chronic kidney disease (CKD), and renal insufficiency. A propensity score from 0 to 1 was generated from this model and assigned to each subject. A nearest neighbor 1:1 variable ratio with propensity scores that fell within a caliper of 0.02 was then used to generate matched cohorts hypothesized to be balanced of potentially confounding baseline characteristics.

A backward method multivariable logistic regression was performed for overall and bariatric-related morbidity. Factors with a difference (*p* \< .05) on univariate analysis between the two racial cohorts were included in the model: race (Black vs. White), Hispanic ethnicity, hypertension, chronic steroid use, and dialysis-dependent CKD in our multivariate logistic regression analyses. A procedure-specific multivariable regression analysis was performed for sleeve gastrectomy and gastric bypass cases independently. For each procedure, race and variables that were significantly (*p* \< .05) on univariate analysis were included in the multivariate regression models. For SG cases, variables included in the regression algorithm were race, Hispanic ethnicity, gender, and OSA. For RYGB, variables included race, ethnicity, body mass index (BMI), and renal insufficiency.

For univariate unmatched and matched analyses, primary and secondary outcomes were compared by Pearson Chi-Square test for categorical variables and Mann-U-Whitney for continuous variables. Continuous data is expressed as median and interquartile range (IQR) and categorical data is expressed as frequency and percentage. All statistical analyses were performed with SPSS version 26 (IBM Corporation, Armonk, NY) and SAS version 9.4 (SAS Institute, Cary, NC). A *p* value of \< 0.05 was considered statistically significant.

Results {#Sec6}
=======

Patient Demographics {#Sec7}
--------------------

Of the 200,374 cases in the 2017 MBSAQIP database, 0.3% (*n* = 614) had a PSOT. Following exclusions, 335 patients with a prior solid organ transplant were analyzed, including 250 white and 85 black patients. Thirty-four percent (*n* = 208) of the transplant cohort was excluded for CPT codes associated with procedures other than RYBG and SG. Characteristics of the unmatched racial cohorts are detailed in Table [1](#Tab1){ref-type="table"}. Patient demographics (age, gender, and body mass index), operative characteristics (procedure type (RYGB vs. SG), surgical approach (conventional laparoscopy vs. robotic-assisted)), and most preoperative comorbidities were similar between racial cohorts. Black patients had significantly higher rates of hypertension (77% vs. 64%, *p* = 0.03), chronic steroid use (52% vs. 38%, *p* = 0.03), and dialysis-dependent chronic kidney disease (15% vs. 6.8%, *p* = 0.02).Table 1Unmatched patient characteristicsTotal\
(*n* = 335)White\
(*n* = 250)Black\
(*n* = 85)*p* ValueEffect sizeContinuous variables, median  Age, years49 (41--58)49 (41--59)48 (41--57)0.3170.1742.1 (38.5-41.6 (38.5-42.9 (38.6-  BMI, kg/m246.2)46.2)46.2)0.4670.14Categorical variables, *n*, (%)  Gender, female237 (71)173 (69)64 (75)0.2861.26  Ethnicity (Hispanic)46 (14)45 (18)1 (1.2)**\< 0.001**13  ASA class \> 3297 (89)218 (87)79 (93)0.1491.93  Operation type0.1411.42    Sleeve252 (75)183 (73)69 (81)    Gastric bypass83 (25)67 (27)16 (19)  Surgical approach0.4540.92    Laparoscopic309 (92)229 (92)80 (94)    Robotic26 (8)21 (8)5 (6)  History of myocardial infarction9 (2.7)8 (3.2)1 (1.2)0.4582.32  History of PCI16 (4.8)13 (5.2)3 (3.5)0.5331.37  History of Cardiac Surgery23 (6.9)20 (8.0)3 (3.5)0.1592.02  Hypertension225 (67)160 (64)65 (77)**0.034**1.83  Diabetes mellitus117 (35)92 (37)25 (29)0.2170.92  Hyperlipidemia135 (40)103 (41)32 (38)0.5641.12  Gastroesophageal reflux disease143 (43)112 (45)31 (37)0.1801.30  COPD4 (1.2)4 (1.6)0 (0)0.2410.74  Obstructive sleep apnea118 (35)95 (38)23 (27)0.0680.89  Oxygen dependent4 (1.2)3 (1.2)1 (1.2)0.9861.02  Smoker11 (3.3)8 (3.2)3 (3.5)0.8831.11  Renal insufficiency47 (14)30 (12)17 (20)0.0671.83  Dialysis30 (9)17 (6.8)13 (15)**0.018**2.50  DVT14 (4.2)9 (3.6)5 (5.9)0.3641.67  Pulmonary embolism11 (3.3)6 (2.4)5 (5.9)0.1202.54  IVC filter6 (1.8)3 (1.2)3 (3.5)0.1621.50  Anticoagulation24 (7.2)15 (6)9 (11)0.1561.72  Chronic steroids140 (42)96 (38)44 (52)**0.031**1.72  Limited ambulation status9 (2.7)5 (2.0)4 (4.7)0.2392.42  Independent functional status329 (98)247 (99)82 (97)0.1702.01  Prior bariatric/foregut surgery23 (6.9)19 (7.6)4 (4.7)0.3621.49*IQR* interquartile range, *BMI* body mass index (kg/m^2^), *ASA* American society of anesthesiologists, *PCI* percutaneous coronary intervention, *COPD* chronic obstructive pulmonary disease, *DVT* deep vein thrombosis, *IVC* inferior vena cava, *Bold* statistically significant, *p* \< 0.05

Outcomes Following Unmatched Analysis {#Sec8}
-------------------------------------

Primary and secondary outcome measures were compared in the unmatched racial cohorts and are detailed in Table [2](#Tab2){ref-type="table"}. Overall mortality and morbidity were 0.3% and 12%, respectively. All-cause mortality (0% vs. 0.4%, *p* = 1.0) and morbidity (17% vs. 10%, *p* = 0.1) were similar between black and white patients. Bariatric-related morbidity was twofold higher in black patients (14% vs. 7.2%) and trended towards significance (*p* = 0.05). In unmatched cohort analysis, black patients had higher rates of postoperative pneumonia (*p* = 0.02), acute renal failure (*p* = 0.02), aggregate pulmonary complications (*p* = 0.02), and emergency (ED) department visit (*p* = 0.03). All other outcome measures were similar (Table [2](#Tab2){ref-type="table"}).Table 2Unmatched perioperative outcomesTotal\
(*n* = 335)White\
(*n* = 250)Black\
(*n* = 85)*p* ValueHospital outcomes, median (IQR)  Operative time, minutes97 (64--136)100 (63--135)94 (64--138)0.853  Length of stay, days2 (1--2)2 (1--2)2 (1--3)0.09130-day adverse outcomes and postoperative complications, *n*, (%)  Overall mortality1 (0.3)1 (0.4)0 (0)1.000  Bariatric-related mortality1 (0.3)1 (0.4)0 (0)1.000  Overall morbidity39 (12)25 (10)14 (17)0.108  Bariatric-related morbidity30 (9)18 (7.2)1 (14)0.054  Reoperation6 (1.8)4 (1.6)2 (2.4)0.651  Reoperation related6 (1.8)4 (1.6)2 (2.4)0.651  Readmission33 (10)21 (8.4)12 (14)0.126  Readmission related27 (8.1)16 (6.4)11 (13)0.056  Postoperative intervention9 (2.7)5 (2.0)4 (4.7)0.183  Postoperative intervention related9 (2.7)5 (2.0)4 (4.7)0.183  Unplanned ICU admission10 (3.0)5 (2.0)5 (5.9)0.069  Perioperative transfusions9 (2.7)7 (2.8)2 (2.4)0.826  Myocardial infarction1 (0.3)1 (0.4)0 (0)0.559  Pulmonary embolism2 (0.6)1 (0.4)1 (1.2)0.422  Pneumonia2 (0.6)0 (0)2 (2.4)**0.015**  Superficial SSI4 (1.2)4 (1.6)0 (0)0.598  Deep incisional SSI1 (0.3)1 (0.4)0 (0)0.559  Organ space infection4 (1.2)4 (1.6)0 (0)0.241  Sepsis1 (0.3)1 (0.4)0 (0)0.559  Progressive renal insufficiency4 (1.2)4 (1.6)0 (0)0.241  Acute renal failure2 (0.6)0 (0)2 (2.4)**0.015**  Urinary tract infection1 (0.3)1 (0.4)0 (0)0.559  *Clostridium difficile*1 (0.3)1 (0.4)0 (0)0.559  Emergency department visits25 (7.5)14 (5.6)11 (13)**0.026**  Approach converted5 (1.5)3 (1.2)2 (2.4)0.449Aggregate complications, *n (%)*  Bleeding1 (0.3)1 (0.4)0 (0)0.559  Anastomotic leak7 (2.1)7 (2.8)0 (0)0.119  Cardiovascular2 (2.6)2 (0.8)0 (0)0.408  Pulmonary2 (2.6)0 (0)2 (2.4)**0.015**  Renal6 (1.8)4 (1.6)2 (2.4)0.651  Venous thromboembolic5 (1.5)3 (1.2)2 (2.4)0.449  Surgical site infections10 (3)10 (4.0)0 (0)0.061*IQR* interquartile range, *ICU* intensive care unit, *SSI* surgical site infection, *Bold* statistically significant, *p \< 0.05*

Outcomes Following Propensity Score Matching and Multivariate Logistic Regression Analysis {#Sec9}
------------------------------------------------------------------------------------------

One-to-one propensity score analysis compared 82 black and 82 white MBS patients with PSOT that were statistically similar (*p* \> 0.1) at baseline (Supplementary Table [1](#MOESM1){ref-type="media"}). Perioperative outcomes after propensity score matching are outlined in Table [3](#Tab3){ref-type="table"}*.* There was no mortality in either cohort. Overall (17% vs. 10%, *p* = 0.2) and bariatric-related morbidity (15% vs. 8.5%, *p* = 0.2) were statistically similar between black and white patients. All other outcome measures were also similar between racial cohorts. Multivariate regression analyses were performed to identify independent predictors of overall and bariatric-related morbidity as shown in Table [4](#Tab4){ref-type="table"}***.*** Black race was not found to be an independent predictor of overall morbidity (OR 1.6, *p* = 0.2) or bariatric-related morbidity (OR 1.78, p = 0.2). Both overall and bariatric-related morbidities were independently associated with chronic steroid use.Table 3Propensity score--matched perioperative outcomesTotal\
(*n* = 164)White\
(*n* = 82)Black\
(*n* = 82)*p* ValueHospital outcomes, median (IQR)  Operative time, minutes95 (63--139)95 (57--151)95 (65--137)0.732  Length of stay, days2 (1--3)2 (1--2)2 (1--3)0.64930-day adverse outcomes and postoperative complications *n*, (%)  Overall morbidity22 (13)8 (10)14 (17)0.169  Bariatric-related morbidity19 (12)7 (8.5)12 (15)0.222  Reoperation3 (1.8)1 (1.2)2 (2.4)0.560  Reoperation related3 (1.8)1 (1.2)2 (2.4)0.560  Readmission19 (12)7 (8.5)12 (15)0.222  Readmission related18 (11)7 (8.5)11 (13)0.318  Postoperative intervention5 (3.0)1 (1.2)4 (4.9)0.173  Postoperative intervention related5 (3.0)1 (1.2)4 (4.9)0.173  ICU admission8 (4.9)3 (3.7)5 (6.1)0.468  Perioperative transfusions6 (3.7)4 (4.9)2 (2.4)0.405  Myocardial infarction1 (0.6)1 (1.2)0 (0)0.316  Pulmonary embolism1 (0.6)0 (0)1 (1.2)0.316  Pneumonia2 (1.2)0 (0)2 (2.4)0.155  Deep incisional SSI1 (0.6)1 (1.2)0 (0)0.316  Organ space infection1 (0.6)1 (1.2)0 (0)0.316  Progressive renal insufficiency3 (1.8)3 (3.7)0 (0)0.080  Acute renal failure2 (1.2)0 (0)2 (2.4)0.155  Urinary tract infection1 (0.6)1 (1.2)0 (0)0.316  *Clostridium difficile*1 (0.6)1 (1.2)0 (0)0.316  Emergency department visits14 (8.5)4 (4.9)10 (12)0.094  Approach converted2 (1.2)1 (1.2)1 (1.2)1.000Aggregate complications, *n* (%)  Bleeding0 (0)0 (0)0 (0)--  Anastomotic leak4 (2.4)4 (4.9)0 (0)0.120  Cardiovascular1 (0.6)1 (1.2)0 (0)0.316  Pulmonary2 (1.2)0 (0)2 (2.4)0.155  Renal5 (3.0)3 (3.7)2 (2.4)0.650  Venous thromboembolic4 (2.4)2 (2.4)2 (2.4)1.000  Surgical site infections3 (1.8)3 (3.7)0 (0)0.080*IQR* interquartile range*, ICU* intensive care unit*, SSI* surgical site infectionTable 4Multivariable regression for risk factors associated with overall and bariatric-related morbidityOdds ratio95% CI*p* ValueOverall morbidity  Race (Black vs. White)1.600.76--3.820.218  Preoperative steroid use2.401.17--4.92**0.017**  Preoperative dialysis1.040.33--3.260.941  Hispanic1.000.35--2.830.993  Hypertension0.950.43--2.070.890Bariatric-related morbidity  Race (Black vs. White)1.780.79--4.020.168  Preoperative steroid use2.251.05--4.84**0.038**  Preoperative dialysis1.480.47--4.710.506  Hypertension1.320.53--3.320.556  Hispanic0.810.22--2.930.747*Bold* statistically significant, *p \<* 0.05

Procedure-Specific Analysis {#Sec10}
---------------------------

Subgroup analyses of SG (*n* = 252) and RYGB (*n* = 83) cohorts were performed. Descriptive statistics of these procedure-specific analyses are detailed in Supplementary Table [2](#MOESM2){ref-type="media"}***.*** For SG cases, female sex (*p* = 0.04) was more prevalent in black patients and preoperative obstructive sleep apnea (*p* = 0.03) was more prevalent in white patients. For RYGB cases, preoperative BMI (*p* = 0.03) and renal insufficiency (19% vs. 3%, *p* = 0.05) were higher in black patients. For both SG and RYGB, all other patient demographics and preoperative comorbidities were similar between racial cohorts. Outcomes of these unmatched procedure-specific subgroup analyses are reported in Supplementary Table [3](#MOESM3){ref-type="media"}. Mortality was 0--0.5% (*p* \> 0.5). There were no procedure-specific statistically significant racial differences in overall or bariatric-related morbidity; however, morbidity was higher in black patients for both SG and RYGB cases. For SG, there was a higher rate of aggregate pulmonary complications (2.9% vs. 0%, *p* = 0.07) and ED visits (10% s. 3.8%, *p* = 0.05), though it did not reach statistical significance. For RYGB cases, there was an 8.6-fold higher likelihood of ICU admission for black patients; however, the difference was not statistically significant (*p* = 0.09). Procedure-specific multivariate regression analyses were performed and results are detailed in Table [5](#Tab5){ref-type="table"}. For SG cases, black race was associated with a higher likelihood of overall (OR 2.3, CI 0.92--5.73, *p* = 0.07) and bariatric-related morbidity (OR 2.78, CI 0.98--7.89, *p* = 0.06), but not significantly so. Obstructive sleep apnea also independently correlated with bariatric-related morbidity (OR 2.95, CI 1.06--8.24, *p* = 0.04). While overall (OR 2.08) and bariatric related (OR 2.52) morbidity were also higher in black patients after RYGB, the differences were not significant (Table [6](#Tab6){ref-type="table"}).Table 5Multivariable regression for risk factors associated with overall and bariatric-related morbidity in SG patientsOdds ratio95% CI*p* ValueOverall morbidityRace (Black vs. White)2.300.92--5.730.074Obstructive sleep apnea2.390.99--5.770.052Hispanic1.160.31--4.360.825Male (vs. Female)1.100.44--2.750.836Bariatric-related morbidityRace (Black vs. White)2.780.98--7.890.055Obstructive sleep apnea2.951.06--8.24**0.039**Hispanic1.110.23--5.440.898Male (vs. Female)0.940.32--2.760.906*SG* sleeve gastrectomy, *Bold* statistically significant, *p* \< 0.05Table 6Multivariable regression for risk factors associated with overall and bariatric-related morbidity in RYGB patientsOdds ratio95% CI*p* ValueOverall morbidityRace (Black vs. White)2.080.48--9.090.330Hispanic0.990.18--5.450.993Preoperative renal insufficiency0.880.08--9.610.917BMI0.650.11--3.720.626Bariatric-related morbidityRace (Black vs. White)2.520.55--11.50.233Preoperative renal insufficiency1.010.09--11.40.992Hispanic0.550.06--5.010.593BMI0.500.08--2.980.449Race (Black vs. White)2.520.55--11.50.233*RYGB* Roux-en-Y gastric bypass, *BMI* body mass index, *Bold* statistically significant, *p* \< 0.05

Discussion {#Sec11}
==========

This is the first and largest study reporting on disparity in outcomes following metabolic and bariatric surgery in racial cohorts with a history of prior solid organ transplantation. In this analysis, we have reinforced the safety of MBS in transplant patients, showing a low rate of overall mortality (0.3%), overall morbidity (12%), bariatric-related mortality (0.3%), and bariatric-related morbidity (9%). This is consistent with the published literature on perioperative outcomes following MBS. The systematic review of randomized and observational studies (*n* = 161,756) by Chang et al. \[[@CR3]\] reported mortality and morbidity rates of 0.22--0.35% and 9.8%, respectively, following metabolic and bariatric surgery. Following propensity score--matched analyses in our study, there were no statistically significant differences in hospital outcomes, 30-day adverse outcomes, and postoperative or aggregate complications between racial cohorts. Nonetheless, the rates of readmission (1.8-fold), reoperation (2-fold), reintervention (4-fold), and emergency department (ED) visits (2.4-fold) were higher in black patients. On multivariate regression analysis, black race was not found to be an independent predictor of all-cause or bariatric-related morbidity. While race was not an independent predictor of outcomes in this cohort of MBS patients with prior solid organ transplantation, chronic steroid use was.

The nonsignificant differences in outcomes noted between black and white patients in this study are consistent with prior studies reporting a lack of significant correlation between race and MBS outcomes \[[@CR21]--[@CR23]\]. However, the nonsignificantly higher rates of some adverse outcomes (reoperation, readmission, reintervention) in black patients in our study are concerning and need further exploration with larger patient cohorts. It is possible that these differences represent racial disparity in outcomes, but given the small sample sizes, the study had inadequate power to show a statistically significant difference.

Upon multivariable regression analysis of SG and RYGB cases independently, black race was associated with a high odds ratio (OR \> 2) for both overall and bariatric-related morbidity, more so with SG. However, these differences did not reach statistical significance. In our study, we also notice a trend toward a higher rate of ED visits (2.6-fold) in black SG patients. The reasons for this finding remain unclear and could not be elucidated from the database used for our study. In the published literature, the most common reported reasons for ED visits including abdominal pain, nausea/vomiting, dehydration, wound concerns, and compliance issues \[[@CR26]--[@CR29]\]. In a recent prospective cohort study of patients in the Michigan Bariatric Surgery Collaborative (MBSC) database, Stevens et al. \[[@CR26]\] found that most ED presenting symptoms following bariatric surgery were of low acuity and non-life-threatening. Some studies have highlighted educational level as a possible contributor to poor compliance, resulting in higher readmission rates. Mahoney et al \[[@CR30]\] evaluated grade level education (survey) and health literacy using the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF) health literacy test and found that educational level less than or equal to 12th grade was associated with a threefold higher rate of ED visits and readmissions following bariatric surgery. No correlation was found between health literacy and ED visits. Others have reported patient demographics, such as younger age and female sex as potential predictors of ED visits \[[@CR28]\]. Given the higher associated healthcare cost from ED visits and readmissions, there is increasing interest to improve this MBS quality metric. Further studies to differentiate reasons for ED visits and readmissions between racial cohorts and high-risk patient cohorts (e.g., prior transplantation) may further our understanding of this quality metric and highlight opportunities for improvement, efficiency, and cost-savings. In contrast to numerous studies showing a higher rate of adverse outcomes following RYGB compared with SG, in our procedure-specific analyses of racial bariatric surgery cohorts with prior solid organ transplantation, there were no significant differences in outcomes between RYGB and SG cases.

While our study demonstrated that outcomes in this cohort of MBS patients are not mediated by race, there are several study limitations to consider. First, this is a retrospective analysis that is subject to the inherent biases of such an analysis. Second, a significant portion of transplant cases were excluded, primarily because of CPT codes not specific to SG or RYGB. Even though this represents the largest study in this cohort of patients, generalizability is limited by the overall small sample size analyzed. In addition, several granular data points are not included in the database and therefore could not be accounted for in our analysis. Such data points include the type of solid organ transplantation performed, timeframe from transplantation to bariatric surgery, and the immunosuppressive regimen of each patient. The timeframe between organ transplantation and metabolic and bariatric surgery may impact intraoperative findings, operative course, and ultimately perioperative outcomes. The inability to account for these confounders may have an impact on our findings.

Conclusion {#Sec12}
==========

Metabolic and bariatric surgery in racial cohorts of post-solid organ transplantation patients is safe, with very low rates of morbidity and mortality. While some adverse outcomes were higher in black patients, race was not found to be an independent predictor of adverse outcomes following SG or RYGB in patients with prior solid organ transplantation. However, there were trends toward higher rates of adverse outcomes, including overall and bariatric-related morbidity, in both propensity score--matched and multivariate regression analyses. Given the sample size limitation of our study, additional analyses of larger cohorts are needed to further explore the impact of race on outcomes in bariatric surgery patients with prior organ transplantation.
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Table 7Composite complication methodologyAggregate variableComposite variablesLeakReoperation with suspected reason: leakReadmission with suspected reason: leakIntervention with suspected reason: leakDrain present over 30 daysComplication: organ space SSIBleedingReoperation with suspected reason: bleedingReadmission with suspected reason: bleedingIntervention with suspected reason: bleedingCardiac/CVAReoperation with suspected reason: cardiac NOS, CVA, or MIReadmission with suspected reason: cardiac NOS, CVA, or MIIntervention with suspected reason: cardiac NOS, CVA, or MIComplication of CVAComplication of MIPulmonaryReoperation with suspected reason: shortness of breath, pneumonia, or other respiratory failureReadmission with suspected reason: shortness of breath, pneumonia, or other respiratory failureIntervention with suspected reason: shortness of breath, pneumonia, or other respiratory failureComplication: on ventilator \> 48 hComplication: unplanned intubationComplication: pneumoniaRenalReoperation with suspected reason: renal insufficiencyReadmission with suspected reason: renal insufficiencyIntervention with suspected reason: renal insufficiencyComplication: progressive renal insufficiencyComplication: acute renal failureDVT or PEReoperation with suspected reason: vein thrombosis requiring therapy or pulmonary embolismReadmission with suspected reason: vein thrombosis requiring therapy or pulmonary embolismIntervention with suspected reason: vein thrombosis requiring therapy or pulmonary embolismComplication: vein thrombosis requiring therapyComplication: pulmonary embolismComplication: anticoagulation initiated of presumed/confirmed vein thrombosis/PEWound infectionReoperation with suspected reason: wound infection or other abdominal sepsisReadmission with suspected reason: wound infection or other abdominal sepsisIntervention with suspected reason: wound infection or other abdominal sepsisComplication: post-op superficial incisional SSI occurrenceComplication: post-op deep incisional SSI occurrenceOther infectionReoperation with suspected reason: infection/feverReadmission with suspected reason: infection/fever,Intervention with suspected reason: infection/feverComplication: post-op sepsis occurrenceComplication: post-op septic shock occurrenceComplication: post-op pneumonia occurrenceComplication: post-op urinary tract infection occurrenceOverall morbidityMortality within 30 daysNeed for intervention within 30 daysNeed for readmission within 30 daysNeed for reoperation within 30 daysUnplanned ICU transfer within 30 daysAggregate-related reoperationAny reoperation designated as related to metabolic/bariatric by variable REOP_RELATED_BAR1. To REOP_RELATED_BAR.13Aggregate-related readmissionAny readmission designated as related to metabolic/bariatric by variable READ_RELATED_BAR1. To READ_RELATED_BAR.11Aggregate-related interventionAny intervention designated as related to metabolic/bariatric by variable INVT_RELATED_BAR1. To INTV_RELATED_BAR.5Bariatric surgery--related morbidityDeath related to bariatric surgeryAggregate reoperation related to metabolic/bariatric surgeryAggregate readmission related to metabolic/bariatric surgeryAggregate intervention related to metabolic/bariatric surgery
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